Abstract
ABSTRACT This study is aimed to review the published evidence on safety, immunogenicity, and efficacy of rotavirus vaccines when co-administered with meningococcal vaccines in infants. A systematic literature search was performed in four databases containing peer-reviewed articles and conference abstracts. In total, twelve articles were included in the review; 11 provided information on safety and five on the immunogenicity of rotavirus vaccines following co-administration. No paper was found on efficacy. Additional routine vaccines were administered in all studies. The safety analysis was mainly focused on fever, vomiting, diarrhea, intussusception, and changes in eating habits. Overall, safety profiles and immune responses associated with rotavirus vaccination were comparable between infants co-administered with rotavirus and meningococcal vaccines and infants receiving rotavirus vaccines without meningococcal vaccines. Although data are limited, co-administration of rotavirus and meningococcal vaccines does not appear to interfere with the safety or immunogenicity of rotavirus vaccines.
Highlights
Rotavirus (RV) is a common cause of severe and fatal acute diarrhea in young children throughout the world.[1]
This study is aimed to review the published evidence on safety, immunogenicity, and efficacy of rotavirus vaccines when co-administered with meningococcal vaccines in infants
Safety profiles and immune responses associated with rotavirus vaccination were comparable between infants co-administered with rotavirus and meningococcal vaccines and infants receiving rotavirus vaccines without meningococcal vaccines
Summary
Rotavirus (RV) is a common cause of severe and fatal acute diarrhea in young children throughout the world.[1]. In the European Union, 300–600 children per 100,000 under the age of 5 years are hospitalized due to RV gastroenteritis (RVGE) annually.[2]. The human live-attenuated RV vaccine containing G1P[8] strain (HRV, Rotarix) is administered as a two-dose schedule, with a minimum interval of 4 weeks between doses, the first dose being administered from 6 weeks of age. The human-bovine live-attenuated reassortant pentavalent RV vaccine (HBRV, RotaTeq) is administered as a three-dose regimen, with an interval of at least 4 weeks between doses, the first dose being administered between 6 and 12 weeks of age. New liveattenuated naturally reassorted monovalent (nHRV, Rotavac) and human-bovine reassortant pentavalent (BRV-PV, Rotasiil) RV vaccines have been recently licensed.[9,10]. All these four vaccines are WHO prequalified.[11] The schedule must be completed by 32 weeks of age.[7,8] new liveattenuated naturally reassorted monovalent (nHRV, Rotavac) and human-bovine reassortant pentavalent (BRV-PV, Rotasiil) RV vaccines have been recently licensed.[9,10] All these four vaccines are WHO prequalified.[11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
